Evidence map›Paper›PMID 35877003›Full record

ArticleCellular and molecular life sciences : CMLS2022

Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage.

Haibin Deng, Yanyun Gao, Verdiana Trappetti, Damian Hertig, Darya Karatkevich, Tereza Losmanova, Christian Urzi, Huixiang Ge, Gerrit Adriaan Geest, Remy Bruggmann and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 54 citations in OpenAlex.

  1. LDH isozymes as targets for cancer therapy.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Review
  3. Review
  4. Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Inhibition Profiling ofMolecules (Basel, Switzerland) · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Haibin DengDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Yanyun GaoDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Verdiana TrappettiInstitute of Anatomy, University of Bern, Bern, Switzerland.
Damian HertigDepartment of Neuroradiology, University of Bern, Bern, Switzerland.
Darya KaratkevichDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Tereza LosmanovaInstitute of Pathology, University of Bern, Bern, Switzerland.
Christian UrziDepartment of Neuroradiology, University of Bern, Bern, Switzerland.
Huixiang GeDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Gerrit Adriaan GeestInterfaculty Bioinformatics Unit, Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.
Remy BruggmannInterfaculty Bioinformatics Unit, Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.
Valentin DjonovInstitute of Anatomy, University of Bern, Bern, Switzerland.
Jean-Marc NuofferDepartment of Neuroradiology, University of Bern, Bern, Switzerland.
Peter VermathenTranslational Imaging Center (TIC), Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland.
Nicola ZamboniInstitute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Carsten RietherDepartment for BioMedical Research, University of Bern, Bern, Switzerland.
Adrian OchsenbeinDepartment for BioMedical Research, University of Bern, Bern, Switzerland.
Ren-Wang PengDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Gregor Jan KocherDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Ralph Alexander SchmidDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland. ralph_a_schmid@hotmail.com.
Patrick DornDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland. patrick.dorn@insel.ch.
Thomas Michael MartiDepartment of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland. thomas.marti@insel.ch.ORCID http://orcid.org/0000-0003-3005-220X
University of Bern · CHETH Zurich · CH

Funding

Krebsliga Schweiz KFS-5405-08-2021-R
6 · The paper itself

Abstract

Once considered a waste product of anaerobic cellular metabolism, lactate has been identified as a critical regulator of tumorigenesis, maintenance, and progression. The putative primary function of lactate dehydrogenase B (LDHB) is to catalyze the conversion of lactate to pyruvate; however, its role in regulating metabolism during tumorigenesis is largely unknown. To determine whether LDHB plays a pivotal role in tumorigenesis, we performed 2D and 3D in vitro experiments, utilized a conventional xenograft tumor model, and developed a novel genetically engineered mouse model (GEMM) of non-small cell lung cancer (NSCLC), in which we combined an LDHB deletion allele with an inducible model of lung adenocarcinoma driven by the concomitant loss of p53 (also known as Trp53) and expression of oncogenic KRAS (G12D) (KP). Here, we show that epithelial-like, tumor-initiating NSCLC cells feature oxidative phosphorylation (OXPHOS) phenotype that is regulated by LDHB-mediated lactate metabolism. We show that silencing of LDHB induces persistent mitochondrial DNA damage, decreases mitochondrial respiratory complex activity and OXPHOS, resulting in reduced levels of mitochondria-dependent metabolites, e.g., TCA intermediates, amino acids, and nucleotides. Inhibition of LDHB dramatically reduced the survival of tumor-initiating cells and sphere formation in vitro, which can be partially restored by nucleotide supplementation. In addition, LDHB silencing reduced tumor initiation and growth of xenograft tumors. Furthermore, we report for the first time that homozygous deletion of LDHB significantly reduced lung tumorigenesis upon the concomitant loss of Tp53 and expression of oncogenic KRAS without considerably affecting the animal's health status, thereby identifying LDHB as a potential target for NSCLC therapy. In conclusion, our study shows for the first time that LDHB is essential for the maintenance of mitochondrial metabolism, especially nucleotide metabolism, demonstrating that LDHB is crucial for the survival and proliferation of NSCLC tumor-initiating cells and tumorigenesis.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsCarcinogenesisCell Line, TumorCell ProliferationDNA, MitochondrialHomozygoteHumansIsoenzymesLactatesL-Lactate DehydrogenaseMiceMitochondriaNeoplastic Stem CellsNucleotidesDNA, MitochondrialIsoenzymeslactate dehydrogenase 1LactatesL-Lactate DehydrogenaseNucleotidesProto-Oncogene Proteins p21(ras)Cancer stem cellsCellular plasticityLung cancerMitochondrial DNAMitochondrial metabolismNucleotide metabolismTumorigenicity

Identifiers

PMID35877003
PMCPMC9314287
OpenAlexW4287092179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.